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NAA=N-acetyl aspartateAbstract Aim of work: The purpose of this study is to assess the sensitivity of Proton MRS to dif-
ferentiate between tumor recurrence and newly contrast enhanced radiation sequel.
Patients and methods: The study was conducted from May 2011 to June 2014 and the study pop-
ulation included 29 patients, 18 males and 11 females with age ranging from 10 to 68 years old
(mean = 39) who had been initially diagnosed with an IC neoplasm.
Results: Proton MRS performed over the recurrent contrast enhancing lesions resulted in quanti-
ﬁable choline, creatine, NAA, and lactate peaks in 28 (97%) of the 29 patients.
Lesions in the recurrent or residual tumor group had higher Cho/Cr ratios and higher Cho/Cr
ratios.
Lesions in the recurrent or residual tumor group also had higher Cho/NAA ratios and higher Cho/
NAA ratios than the normal-appearing white matter of 26 patients (p< 0.0001; SE, 0.08).
Lesions in the recurrent or residual tumor group had lower NAA/Cr ratios (p< 0.0001; SE, 0.09)
than those in the radiation injury group, and lower NAA/Cr ratios than the normal-appearing
white matter of 26 patients (p= 0.075; SE, 0.09).
Conclusion: We conclude that Proton MRS has the potential to discriminate between recurrent
tumor and radiation sequel in patients with recurrent contrast-enhancing intracranial lesions.
 2014 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V. All rights reserved.1. Introduction
A deﬁnite diagnosis and differentiation between recurrent
tumor and radiation sequel of a previously treated brain
lesion, based on structural Magnetic Resonance Imaging
(MRI) alone may be difﬁcult. In such cases Proton Magnetic
Resonance Spectroscopy (H1MRS) along with other non-invasive techniques represents an advance in the speciﬁcity of
brain lesion diagnosis (1).
Proton Magnetic Resonance Spectroscopy gives completely
different information related to cell membrane proliferation,
neuronal damage, energy metabolism and necrotic transforma-
tion of the brain or tumor tissues (2).
Multivoxel spectroscopic imaging enables coverage of a lar-
ger volume and investigation of multiple regions of the lesion
and surrounding tissue. One could assume that the smaller the
sampling unit, the more speciﬁc Proton MRS will be in these
heterogeneous lesions (3). However, lesions in the posteriored.
132 G.H. Gamalfossa and those supratentorial lesions that lie in close proxim-
ity to the ventricular system or skull are difﬁcult to evaluate
with Proton MRS because of bulk magnetic susceptibility
variations. This problem can be largely overcome by using
both outer volume suppression slices and in-ﬁeld-of-view
saturation bands for the suppression of bone regions adjacent
to the lesion of interest (4).
The aim of this study is to evaluate the sensitivity of Proton
MRS to differentiate between tumor recurrence and newly
contrast enhanced radiation sequel.2. Patients and methods
This study was conducted according to the guidelines of the
Research ethics committee approval and informed consent
was obtained from all patients or from their corresponding
guardian.
It was conducted from May 2011 to June 2014. Patients
were referred to the Radiodiagnosis Department from Neuro-
surgery Department of a specialized hospital.
The study population included a total of 29 patients, 18
males and 11 females with age ranging from 10 to 68 years
(mean = 39). The inclusion criteria were presence of enhanc-
ing brain lesions at follow up MRI in patients with initially
diagnosed intracranial neoplasm, either by biopsy or surgical
resection. All of our patients received radiation therapy and
25 cases received chemotherapy.19 of the 29 patients diag-
nosed to have gliomas (low and high grade), other diagnoses
were: 4 primitive neuroectodermal tumor, 3 medulloblastoma,
1 ependymoma, 1 malignant melanoma, and one lymphoma.
A determination of recurrent tumor versus radiation sequel
was deemed difﬁcult from the imaging characteristics of each
lesion on conventional MRI. Therefore, Proton MRS was
performed to all these patients in an attempt to distinguish
recurrent tumor from radiation sequel.
All the patients had recurrent lesions at the site of their
original supratentorial intraaxial neoplasm, except six patients
had recurrent contrast enhancement at the site of the original
lesion in the posterior fossa, two patients in the brain stem,
and in four patients the lesion was in the cerebellum.
The mean interval between completion of radiation therapy
and the development of a new contrast-enhancing lesion on
scheduled follow-up MRI was 23.4 months (range, 2–108;
median, 16.5 month) in the 16 patients who were classiﬁed as
having recurrent tumor, and 13.9 months (range, 3–36;
median, 13 month) in the 12 patients with lesions classiﬁed
as radiation injury. Clinical, neuroradiologic, and neuropatho-
logic follow-up after Proton MRS was used to establish the
identity of the lesion.
The inclusion criteria for the lesions regarded as tumor
progression were: later veriﬁcation of active tumor at this site
by biopsy (n= 2), surgical resection (n= 5); or continued
progression on subsequent MRI in a manner consistent with
tumor growth (n= 6).
The inclusion criteria for the lesions regarded as radiation
sequel were: later histopathologic evidence of radiation sequel
without tumor by biopsy (n= 4) or surgical resection (n= 2);
or MRI follow-up showing prolonged stability or spontaneous
regression unaccompanied by clinical worsening (n= 7). The
follow-up time of the patients after the initial Proton MRS,
which was performed after initial identiﬁcation of the recurrentcontrast-enhancing lesion, was a mean of 20.5 months (range,
9–34 months; median, 18 months) in patients classiﬁed as
having tumor, and 21.5 months (range, 14–35 months; median,
19 months) in patients whose lesions were classiﬁed as
radiation sequel.
The study was performed on 1.5 Tesla whole body MR sys-
tem (Siemens Magnetom Avanto, PA, USA) using standard
imaging head coil. The contrast medium used in the conven-
tional MR examination was gadopentate dimeglumine
(Magnevist, Bayer Schering, Germany) given intravenously,
the dose: 0.1–0.2 mmol/kg body weight. Adult and adolescent
patients were injected 10 cm and 5 cm of the contrast media,
respectively.
Conventional MRI was performed in conjunction with all
Proton MRS examinations. Initially, each patient was sub-
jected to routine spin echo (SE) sequences, axial, sagittal and
coronal T1 weighted images with and without gadolinium
enhancement, axial T2 with fat suppression, axial FLAIR
and diffusion weighted images. The volume of interest (VOI)
from the lesion was selected on SE-T2-weighted images and
post contrast T1 images for multivoxel MR spectroscopy.
The size of the voxel ranged from 1 · 1 · 1 cm to
2 · 2 · 2 cm according to the size of the lesion. So, the average
scanning time of the whole MRS examination using the multi-
ple voxel technique ranged about 4 min and 20 s. The three TE
sequences (long, short and intermediate TE) were done. Corre-
sponding white matter that appear normal were also analyzed
for the metabolite ratios in long TE. Multivoxel studies were
performed with Point Resolved Spectroscopy (PRESS)
sequence.
The used Proton MRS protocolProton MRS in
- Long TE = 288
- Short TE = 31
- Intermediate TE = 144
with TR = 2000
ﬁeld of view, 16 cm
matrix, 16 · 16
slice thickness, 10–20 mm
acquisition 1 average2.1. Interpretation
The important metabolites to be commented upon their peaks
being decreased, elevated or unchanged were:
In the long TE were: the Cho {at 3.2 parts per million
(ppm)}, NAA (at 2.0 ppm), Cr (3.02 ppm) and as well as
lipid/lactate peaks (between 1 and 1.5 ppm), however, it is
better to comment on them in the short one.
The intermediate TE is done to detect if there is inversion of
the lipid/lactate peak or not, where if seen inverted, so this
denotes lactate. Presence of lipids denotes necrosis, while
lactate denotes neoplastic lesions.
Long TE is done on the apparent normal white matter for
comparison of the ratios.
2.2. Important ratios
The intensity and integral values were obtained for each
metabolite, and then we used the intensity value for obtaining
Sensitivity of Proton MRS 133the important ratios which were essential for reaching the
diagnosis. Cho/NAA (within the lesion) and Ch/Cr (within
both the lesion and the apparently normal side) ratios were
calculated and they were both seen elevated in the neoplastic
lesions. NAA/Cr ratio was calculated.
Metabolite ratios among the recurrent tumor population
and radiation sequel population were compared. The highest
Cho/Cr, Cho/NAA, and NAA/Cr ratios in one voxel were
used for comparison. Two locations in the brain of 26 of 28
patients were measured, one in the contrast-enhancing lesion
and one in the normal-appearing white matter. Measurements
from these two locations in a subject are likely to be correlated.
The generalized estimating equation technique was used to ﬁt a
linear regression model for each of the three ratios to take into
account the within-subject correlation (5,6). Robust SEs were
used to compute Wald test p values. The level for statistical
signiﬁcance was set to a p value of less than 0.05.
3. Results
Proton MRS performed over the recurrent contrast-enhanc-
ing brain lesions resulted in quantiﬁable choline, creatine,
NAA, and lactate peaks in 28 (97%) of the 29 patients.
One patient is not included in the results of this study
because of the signiﬁcant artifacts of his posterior fossa lesion
.On the basis of the clinical and imaging follow-up data or
histopathology results from biopsy or resection, the con-
trast-enhancing lesions of 16 patients were categorized as
tumor recurrence and lesions of 12 patients were categorized
as radiation injury.
By using the generalized estimating equation technique, the
following statistical evaluations were obtained, the lesions in
the recurrent or residual tumor group had signiﬁcantly higher
Cho/Cr ratios than those in the radiation injury group
(p< 0.0001; SE, 0.18), and these, in turn, had signiﬁcantly
higher Cho/Cr ratios than the normal-appearing white matter
of 26 of the patients (p= 0.0003; SE, 0.09).
The lesions in the recurrent or residual tumor group also
had signiﬁcantly higher Cho/NAA ratios than those in the
radiation injury group (p< 0.0001; SE, 0.32), and lesions in
this group again had signiﬁcantly higher Cho/NAA ratios than
the normal-appearing white matter of 26 patients (p< 0.0001;
SE, 0.08). Lesions in the recurrent or residual tumor group had
signiﬁcantly lower NAA/Cr ratios (p< 0.0001; SE, 0.09) than
those in the radiation injury group, which had insigniﬁcantly
lower NAA/Cr ratios than the normal-appearing white matter
of 26 patients (p= 0.075; SE,0.09). The mean values (and
ranges) of the Cho/Cr, Cho/NAA, and NAA/Cr ratios in
respective lesions and normal-appearing white matter are
summarized in Table 1.
Cases with ratio values in the borderline range between
the two types of lesions are given in Table 2. None of theTable 1 Choline, creatine and NAA in recurrent tumor, radiation
Ratio Recurrent tumor (16 patients) Radiation sequ
Cho/Cr 2.52 (1.66–4.26) 1.57 (0.72–1.76
Cho/NAA 3.48 (1.70–6.47) 1.31 (0.83–1.78
NAA/Cr 0.79 (0.47–1.15) 1.22 (0.94–1.69lesions classiﬁed as radiation injury, reached the value of
1.8 in either Cho/Cr or Cho/NAA ratios. Two lesions classi-
ﬁed as radiation injury had Cho/NAA ratios of 1.71 and
1.78, respectively. Both these patients had scattered lesions
in the posterior fossa, with interval regression and no recur-
rent tumor identiﬁed at brain biopsy. Two patients with
tumor who had Cho/Cr ratios lower than 1.8 had Cho/
NAA ratios higher than 1.8 (3.07 and 2.00). One patient with
tumor who had a Cho/NAA ratio less than 1.8, had a Cho/
Cr ratio greater than 1.8 (1.96). Only one patient with tumor
had both Cho/Cr and Cho/NAA ratios lower than 1.8. In
this patient, only parts of the lesion, which was located adja-
cent to mastoid air cells and skull base, could be evaluated
with Proton MRS, and within that area no spectra consistent
with tumor recurrence were evident. The biopsy specimen
that showed tumor was likely taken from another, more
inferior portion of the lesion that was unsuitable for Proton
MRS because of susceptibility artifacts from adjacent
bone and air. When values greater than 1.8 for either
Cho/Cr or Cho/NAA ratios were considered evidence of
tumor, then all but one (27/28) patient with technically
satisfactory Proton MRS could be correctly categorized as
radiation injury or recurrent tumor, within the limits of
reliability of the diagnosis of radiation injury. In the
remaining patient with recurrent tumor that would have been
incorrectly categorized using the 1.8 threshold, incomplete
Proton MRS sampling of parts of the enhancing lesion may
have been a factor. In 6 (38%) of 16 patients with recurrent
or residual tumor, pathologic spectra consistent with the
presence of tumor (i.e., markedly elevated choline and
depressed NAA) were identiﬁed both in voxels placed inside
and in voxels outside the contrast-enhancing lesion. In these
six patients, the highest metabolic ratios were found in the
contrast-enhancing lesion. In no case were the signal
intensities of lactates or lipids alone useful in differentiation
of tumor from radiation injury. Typical examples of
metabolic spectra obtained in areas consistent with radiation
sequel and in areas of recurrent tumor are given in Figs. 1
and 2.
4. Discussion
Sensitivity of Proton MRS in differentiation between tumor
recurrence and newly contrast enhanced radiation sequel
has been shown in this study. Signiﬁcant differences in
Cho/Cr and Cho/NAA ratios were found between recurrent
tumor, radiation injury, and normal-appearing brain. Using
both ratios in a retrospective classiﬁcation (cutoff value, 1.8
for either ratio), all but one patient (97%) would have
received a correct diagnosis from the results of Proton
MRS. This ﬁnding is in accordance with Aydin et al. (7)
study with multivoxel MR spectroscopy, similar signiﬁcantsequel and normal appearing white matter.




Table 2 Borderline ratios between recurrent tumor (4 patients)
and radiation sequel (4 patients).
Recurrent tumor Radiation sequel
Cho/Cr:1.66 (Cho/NAA:1.34) Cho/Cr:1.76 (Cho/NAA:1.11)
Cho/Cr:1.69 (Cho/NAA:3.07) Cho/Cr:1.70 (Cho/NAA:1.01)
Cho/Cr:1.74 (Cho/NAA:2.00) Cho/NAA:1.78 (Cho/Cr:1.64)
Cho/NAA:1.70 (Cho/Cr:1.96) Cho/NAA:1.71 (Cho/Cr:1.61)
Cho = choline, Cr = creatine, NAA=N-acetyl aspartate.
134 G.H. Gamaldifferences were found, and using Cho/Cr and Cho/NAA
ratios allowed a correct retrospective classiﬁcation in more
than 80% of the cases (7,8). Cho/Cr and NAA/Cr ratios in
the recurrent tumor and radiation sequel populations in the
current study are in close agreement with those obtained
using multivoxel MR spectroscopy in similar populations
(9,10), although less overlap between these two populations
exists in the current study using multivoxel MR spectroscopy.
In this speciﬁc group of patients, the magnitude of the range
of metabolite ratios likely reﬂects the heterogeneity of these
lesions with volume averaging of normal and abnormal
tissues (tumor or radiation sequel or combination of both),
although the type and grade of the possible tumor or the
stage of radiation may also contribute. Miller et al. (11)
stated that, spectral patterns do allow reliable differential
diagnostic statements to be made when the tissues are com-
posed of either pure tumor or pure necrosis, but the spectral
patterns are less deﬁnitive when tissues composed of varying
degrees of mixed tumor and necrosis. In that study, a Cho/Cr
ratio of greater than 1.79 had a sevenfold increased
likelihood of being pure tumor (7,11). However, none of
the current study patients with lesions classiﬁed as radiation
sequel had Cho/Cr ratios greater than 1.76, and only three
(19%) of the contributing patients with recurrent tumor              
 
a
Fig. 1 21-year-old female with a previously diagnosed left frontal lo
Axial T1 weighted images after I. V contrast administration show hete
prior resection. (b) MR spectroscopy spectra with increased Cho/NAA
3.21 and 3.24, respectively, and a decrease in the NAA/Cr ratio, 1.01, c
recurrent tumor.had ratios slightly less than 1.76 (Table 2). Thus, indications
are that a threshold value of Cho/Cr or Cho/NAA ratios
(1.8 in the current study) could be used to indicate the pres-
ence of tumor. (5,7,11) reported that, increase in Cho/Cr
ratios and a reduction in NAA/Cr ratios after radiation ther-
apy are proportional to radiation dose, by using single-voxel
MR spectroscopy. In the current study, the Cho/Cr ratios of
lesions related to radiation sequel were signiﬁcantly higher
than those of normal-appearing white matter, whereas the
decrease of NAA/Cr ratios was not signiﬁcant. In the nor-
mal-appearing white matter of the patients included in the
present study, the Cho/Cr ratios (range, 0.86–1.59) are agreed
with those (0.85–1.47) reported previously from single-voxel
MR spectroscopy (0.94 ± 0.17) (12). Also, Cho/NAA ratios
(range, 0.56–1.20) were similar to those in a prior single-voxel
MR spectroscopy study (0.53 ± 0.17) (12). Although the
NAA/Cr ratios for normal appearing white matter in the cur-
rent study (range, 0.64–2.0) are in concordant with those
from single-voxel MR spectroscopy (1.86 ± 0.46) (5), in four
of the included patients with tumor and in two with radiation
sequel the ratios were lower than 1. The normal-appearing
white matter of the present study patients had unavoidably
been subjected to a varying degree of radiation. Because a
decrease in NAA or a reduction in NAA/Cr ratios after
radiation therapy is a frequently reported ﬁnding (5,9,11),
in the current study it is possible that effects of radiation
account in part for the low NAA values of these six patients.
A limitation of this study is that, histopathologic diagnosis
was not available in 13 of 29 patients, and clinical and imaging
follow-up data had to be used as alternative markers for the
identity of the lesion. The prolonged follow-up of these lesions
after Proton MRS should minimize any possibility of
misclassiﬁcation.
It is unlikely that a tumor, once it has shown new enhance-
ment, will show prolonged stability or regression, or that the
patient will improve clinically.b
be malignant brain tumor which has been surgically resected. (a)
rogeneously enhanced areas on 25-month follow-up MRI at site of
(choline–N-acetyl aspartate) and Cho/Cr (choline–creatine) ratios,
onsistent with tumor recurrence. Histopathologically conﬁrmed as
Fig. 2 45-year-old male after surgical resection, radiation, and chemotherapy for left frontal malignant brain tumor. Axial T1-weighted
image after I. V contrast administration shows focal newly enhanced area in right frontal lobe on MR spectroscopy imaging with volume
of interest placed over the lesion. Spectra show mild alterations in metabolic peaks, with slightly increased Cho/Cr (choline–creatine) ratio
(1.76), slightly increased Cho/NAA (choline–N-acetyl aspartate) ratio (1.19), and normal NAA/Cr ratio (1.48), indicating mild elevation
of choline peak. Follow-up showed complete resolution of contrast-enhancing lesion, raising the possibility of radiation sequel.
Sensitivity of Proton MRS 135Among the six patients considered to have a tumor on the
basis of clinical and imaging progression with no histopatho-
logic diagnosis, the progression was monitored for
12–18 months in four patients. The remaining two patients,
who had continued progression over 9 and 16 months, had
Cho/Cr ratios (3 and 4.26) and Cho/NAA ratios (2.75 and
6.19) that were strongly indicative of tumor.
In accordance with other studies (13–16), abnormal meta-
bolic spectra strongly suggestive of tumor in the present study
were also seen outside the contrast enhancing area in 38% of
patients with recurrent tumor. This ability of multivoxel
Proton MRS to detect tumor outside the area of contrast
enhancement lesion may not only increase the chance of
discovering tumor recurrence but may also change the options
for further treatment.
4. Conclusion
We conclude that Proton MRS has the potential to discrimi-
nate between recurrent tumor and radiation sequel in patients
with recurrent contrast-enhancing intracranial lesions.
Proton MRS has proven to be an important complemen-
tary examination in differentiation between brain tumor recur-
rence and radiation sequel in newly enhancing previously
treated brain lesions (7,8).
Further multivoxel studies are needed to determine the
cutoff values of metabolite ratios, with attention to Cho/Cr
and Cho/NAA ratios, which may be the best numeric
discriminators.
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